nodes	percent_of_prediction	percent_of_DWPC	metapath
Amiloride—PLAU—endothelium—sarcoma	0.0193	0.0463	CbGeAlD
Amiloride—PLAU—Complement and Coagulation Cascades—CR2—sarcoma	0.0181	0.0661	CbGpPWpGaD
Amiloride—SLC22A4—larynx—sarcoma	0.0169	0.0404	CbGeAlD
Amiloride—SLC9A1—mammary gland—sarcoma	0.0164	0.0393	CbGeAlD
Amiloride—SCNN1B—mammary gland—sarcoma	0.0148	0.0354	CbGeAlD
Amiloride—SLC9A1—RhoA signaling pathway—EZR—sarcoma	0.0143	0.0523	CbGpPWpGaD
Amiloride—SCNN1A—mammary gland—sarcoma	0.0136	0.0327	CbGeAlD
Amiloride—SLC9A1—Signaling mediated by p38-alpha and p38-beta—MITF—sarcoma	0.0133	0.0485	CbGpPWpGaD
Amiloride—AOC1—embryo—sarcoma	0.0117	0.028	CbGeAlD
Amiloride—SLC9A1—embryo—sarcoma	0.0112	0.0269	CbGeAlD
Amiloride—SCNN1G—seminal vesicle—sarcoma	0.0112	0.0268	CbGeAlD
Amiloride—PLAU—myometrium—sarcoma	0.0111	0.0265	CbGeAlD
Amiloride—ASIC2—tendon—sarcoma	0.0109	0.0262	CbGeAlD
Amiloride—AOC1—hematopoietic system—sarcoma	0.0105	0.025	CbGeAlD
Amiloride—AOC1—connective tissue—sarcoma	0.0101	0.0241	CbGeAlD
Amiloride—SLC9A1—hematopoietic system—sarcoma	0.01	0.024	CbGeAlD
Amiloride—PLAU—seminal vesicle—sarcoma	0.00999	0.0239	CbGeAlD
Amiloride—SLC9A1—connective tissue—sarcoma	0.00964	0.0231	CbGeAlD
Amiloride—SLC9A1—Signaling mediated by p38-alpha and p38-beta—ATF1—sarcoma	0.00958	0.035	CbGpPWpGaD
Amiloride—PLAU—hematopoietic system—sarcoma	0.00949	0.0227	CbGeAlD
Amiloride—PLAU—Beta1 integrin cell surface interactions—COL18A1—sarcoma	0.0092	0.0336	CbGpPWpGaD
Amiloride—PLAU—connective tissue—sarcoma	0.00914	0.0219	CbGeAlD
Amiloride—SLC9A1—smooth muscle tissue—sarcoma	0.00882	0.0211	CbGeAlD
Amiloride—SLC9A1—skin of body—sarcoma	0.00871	0.0208	CbGeAlD
Amiloride—PLAU—smooth muscle tissue—sarcoma	0.00836	0.02	CbGeAlD
Amiloride—PLAU—skin of body—sarcoma	0.00825	0.0198	CbGeAlD
Amiloride—AOC1—Tryptophan metabolism—MDM2—sarcoma	0.00812	0.0297	CbGpPWpGaD
Amiloride—SLC9A1—cardiac atrium—sarcoma	0.0076	0.0182	CbGeAlD
Amiloride—PLAU—cardiac atrium—sarcoma	0.00721	0.0173	CbGeAlD
Amiloride—PLAU—uterus—sarcoma	0.00717	0.0172	CbGeAlD
Amiloride—SLC9A1—lymphoid tissue—sarcoma	0.00705	0.0169	CbGeAlD
Amiloride—AOC1—bone marrow—sarcoma	0.0067	0.016	CbGeAlD
Amiloride—PLAU—lymphoid tissue—sarcoma	0.00668	0.016	CbGeAlD
Amiloride—PLAU—FGF signaling pathway—PLCG1—sarcoma	0.00643	0.0235	CbGpPWpGaD
Amiloride—SLC9A1—bone marrow—sarcoma	0.00642	0.0154	CbGeAlD
Amiloride—PLAU—tendon—sarcoma	0.00628	0.015	CbGeAlD
Amiloride—SCNN1A—uterus—sarcoma	0.00628	0.015	CbGeAlD
Amiloride—PLAU—bone marrow—sarcoma	0.00609	0.0146	CbGeAlD
Amiloride—SCNN1D—testis—sarcoma	0.00584	0.014	CbGeAlD
Amiloride—ASIC1—testis—sarcoma	0.00573	0.0137	CbGeAlD
Amiloride—AOC1—testis—sarcoma	0.00573	0.0137	CbGeAlD
Amiloride—PLAU—Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling—PDGFRB—sarcoma	0.00557	0.0204	CbGpPWpGaD
Amiloride—SCNN1D—liver—sarcoma	0.00552	0.0132	CbGeAlD
Amiloride—SLC9A1—Regulation of Actin Cytoskeleton—EZR—sarcoma	0.00549	0.0201	CbGpPWpGaD
Amiloride—SLC9A1—testis—sarcoma	0.00549	0.0131	CbGeAlD
Amiloride—SLC22A4—mammary gland—sarcoma	0.00547	0.0131	CbGeAlD
Amiloride—PLAU—Beta3 integrin cell surface interactions—PDGFRB—sarcoma	0.00547	0.02	CbGpPWpGaD
Amiloride—AOC1—liver—sarcoma	0.00542	0.013	CbGeAlD
Amiloride—PLAU—testis—sarcoma	0.0052	0.0125	CbGeAlD
Amiloride—SLC9A1—Signaling mediated by p38-alpha and p38-beta—CREB1—sarcoma	0.00519	0.019	CbGpPWpGaD
Amiloride—SLC9A1—liver—sarcoma	0.00519	0.0124	CbGeAlD
Amiloride—SCNN1B—testis—sarcoma	0.00493	0.0118	CbGeAlD
Amiloride—PLAU—liver—sarcoma	0.00492	0.0118	CbGeAlD
Amiloride—PLAU—Osteopontin-mediated events—MMP2—sarcoma	0.0048	0.0176	CbGpPWpGaD
Amiloride—PLAU—amb2 Integrin signaling—MMP2—sarcoma	0.00468	0.0171	CbGpPWpGaD
Amiloride—SCNN1A—testis—sarcoma	0.00456	0.0109	CbGeAlD
Amiloride—PLAU—Beta3 integrin cell surface interactions—KDR—sarcoma	0.00453	0.0166	CbGpPWpGaD
Amiloride—SCNN1A—liver—sarcoma	0.00431	0.0103	CbGeAlD
Amiloride—SCNN1D—lymph node—sarcoma	0.00423	0.0101	CbGeAlD
Amiloride—PLAU—Endochondral Ossification—IGF1R—sarcoma	0.00418	0.0153	CbGpPWpGaD
Amiloride—PLAU—ATF-2 transcription factor network—PDGFRA—sarcoma	0.00418	0.0153	CbGpPWpGaD
Amiloride—PLAU—Validated transcriptional targets of AP1 family members Fra1 and Fra2—MMP2—sarcoma	0.00417	0.0152	CbGpPWpGaD
Amiloride—ASIC1—lymph node—sarcoma	0.00415	0.00994	CbGeAlD
Amiloride—AOC1—lymph node—sarcoma	0.00415	0.00994	CbGeAlD
Amiloride—SLC9A1—ErbB1 downstream signaling—ATF1—sarcoma	0.00398	0.0146	CbGpPWpGaD
Amiloride—SLC9A1—lymph node—sarcoma	0.00398	0.00952	CbGeAlD
Amiloride—SLC22A4—myometrium—sarcoma	0.00388	0.00929	CbGeAlD
Amiloride—PLAU—lymph node—sarcoma	0.00377	0.00903	CbGeAlD
Amiloride—SLC9A1—Signaling mediated by p38-alpha and p38-beta—JUN—sarcoma	0.00373	0.0137	CbGpPWpGaD
Amiloride—PLAU—Osteopontin-mediated events—JUN—sarcoma	0.00371	0.0136	CbGpPWpGaD
Amiloride—SCNN1B—lymph node—sarcoma	0.00357	0.00856	CbGeAlD
Amiloride—SLC22A4—seminal vesicle—sarcoma	0.0035	0.00839	CbGeAlD
Amiloride—SCNN1A—lymph node—sarcoma	0.0033	0.00791	CbGeAlD
Amiloride—PLAU—Validated transcriptional targets of AP1 family members Fra1 and Fra2—CCND1—sarcoma	0.00323	0.0118	CbGpPWpGaD
Amiloride—PLAU—Validated transcriptional targets of AP1 family members Fra1 and Fra2—JUN—sarcoma	0.00322	0.0118	CbGpPWpGaD
Amiloride—PLAU—ATF-2 transcription factor network—CREB1—sarcoma	0.00308	0.0113	CbGpPWpGaD
Amiloride—SLC9A1—RhoA signaling pathway—JUN—sarcoma	0.00305	0.0112	CbGpPWpGaD
Amiloride—PLAU—ATF-2 transcription factor network—MMP2—sarcoma	0.00287	0.0105	CbGpPWpGaD
Amiloride—PLAU—Senescence and Autophagy in Cancer—IGF1R—sarcoma	0.00282	0.0103	CbGpPWpGaD
Amiloride—PLAU—AP-1 transcription factor network—CREB1—sarcoma	0.00269	0.00983	CbGpPWpGaD
Amiloride—PLAU—Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling—SRC—sarcoma	0.00261	0.00955	CbGpPWpGaD
Amiloride—PLAU—Beta3 integrin cell surface interactions—VEGFA—sarcoma	0.0025	0.00912	CbGpPWpGaD
Amiloride—SLC9A1—Signaling mediated by p38-alpha and p38-beta—TP53—sarcoma	0.00246	0.00901	CbGpPWpGaD
Amiloride—SLC9A1—Carbohydrate metabolism—ENO2—sarcoma	0.0024	0.00877	CbGpPWpGaD
Amiloride—PLAU—FGF signaling pathway—JUN—sarcoma	0.00238	0.0087	CbGpPWpGaD
Amiloride—SLC9A1—Endothelins—JUN—sarcoma	0.00233	0.00853	CbGpPWpGaD
Amiloride—PLAU—Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling—EGFR—sarcoma	0.00229	0.00837	CbGpPWpGaD
Amiloride—SLC9A1—Regulation of Actin Cytoskeleton—PDGFRB—sarcoma	0.00224	0.0082	CbGpPWpGaD
Amiloride—PLAU—ATF-2 transcription factor network—CCND1—sarcoma	0.00222	0.00813	CbGpPWpGaD
Amiloride—PLAU—ATF-2 transcription factor network—JUN—sarcoma	0.00222	0.00811	CbGpPWpGaD
Amiloride—SLC9A1—Regulation of Actin Cytoskeleton—PDGFRA—sarcoma	0.00221	0.00807	CbGpPWpGaD
Amiloride—SLC22A4—tendon—sarcoma	0.0022	0.00528	CbGeAlD
Amiloride—SLC9A1—ErbB1 downstream signaling—CREB1—sarcoma	0.00216	0.00788	CbGpPWpGaD
Amiloride—SLC22A4—bone marrow—sarcoma	0.00214	0.00511	CbGeAlD
Amiloride—PLAU—FGF signaling pathway—SRC—sarcoma	0.00214	0.00781	CbGpPWpGaD
Amiloride—SLC9A1—Endothelins—SRC—sarcoma	0.00209	0.00765	CbGpPWpGaD
Amiloride—PLAU—Wnt Signaling Pathway—CCND1—sarcoma	0.00201	0.00734	CbGpPWpGaD
Amiloride—PLAU—Wnt Signaling Pathway—JUN—sarcoma	0.002	0.00732	CbGpPWpGaD
Amiloride—PLAU—AP-1 transcription factor network—IL2—sarcoma	0.00199	0.00727	CbGpPWpGaD
Amiloride—PLAU—Wnt Signaling Pathway—CTNNB1—sarcoma	0.00199	0.00727	CbGpPWpGaD
Amiloride—PLAU—AP-1 transcription factor network—CCND1—sarcoma	0.00194	0.00709	CbGpPWpGaD
Amiloride—PLAU—AP-1 transcription factor network—JUN—sarcoma	0.00193	0.00707	CbGpPWpGaD
Amiloride—PLAU—AP-1 transcription factor network—CTNNB1—sarcoma	0.00192	0.00702	CbGpPWpGaD
Amiloride—PLAU—Hemostasis—TEK—sarcoma	0.00186	0.00681	CbGpPWpGaD
Amiloride—PLAU—Endochondral Ossification—VEGFA—sarcoma	0.00182	0.00664	CbGpPWpGaD
Amiloride—Jaundice—Mitoxantrone—sarcoma	0.00181	0.00587	CcSEcCtD
Amiloride—Cramp muscle—Etoposide—sarcoma	0.00181	0.00586	CcSEcCtD
Amiloride—Tinnitus—Thiotepa—sarcoma	0.0018	0.00584	CcSEcCtD
Amiloride—PLAU—Beta1 integrin cell surface interactions—VEGFA—sarcoma	0.00177	0.00648	CbGpPWpGaD
Amiloride—Alopecia—Thiotepa—sarcoma	0.00171	0.00553	CcSEcCtD
Amiloride—PLAU—Hemostasis—ANGPT2—sarcoma	0.0017	0.00623	CbGpPWpGaD
Amiloride—Bradycardia—Mitoxantrone—sarcoma	0.0017	0.00551	CcSEcCtD
Amiloride—Alopecia—Dactinomycin—sarcoma	0.0017	0.00549	CcSEcCtD
Amiloride—Haemoglobin—Mitoxantrone—sarcoma	0.00168	0.00544	CcSEcCtD
Amiloride—Hyperuricaemia—Epirubicin—sarcoma	0.00167	0.00541	CcSEcCtD
Amiloride—Haemorrhage—Mitoxantrone—sarcoma	0.00167	0.00541	CcSEcCtD
Amiloride—Tension—Thiotepa—sarcoma	0.00165	0.00535	CcSEcCtD
Amiloride—SLC22A1—liver—sarcoma	0.00164	0.00393	CbGeAlD
Amiloride—Nervousness—Thiotepa—sarcoma	0.00164	0.0053	CcSEcCtD
Amiloride—Back pain—Thiotepa—sarcoma	0.00163	0.00527	CcSEcCtD
Amiloride—Neutropenia—Etoposide—sarcoma	0.00162	0.00526	CcSEcCtD
Amiloride—PLAU—Wnt Signaling Pathway—MYC—sarcoma	0.00161	0.00589	CbGpPWpGaD
Amiloride—PLAU—Senescence and Autophagy in Cancer—MDM2—sarcoma	0.00161	0.00588	CbGpPWpGaD
Amiloride—Blood uric acid increased—Epirubicin—sarcoma	0.00158	0.00511	CcSEcCtD
Amiloride—Neck pain—Epirubicin—sarcoma	0.00157	0.00508	CcSEcCtD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—MDM2—sarcoma	0.00156	0.00571	CbGpPWpGaD
Amiloride—PLAU—AP-1 transcription factor network—MYC—sarcoma	0.00155	0.00568	CbGpPWpGaD
Amiloride—Hepatocellular injury—Epirubicin—sarcoma	0.00155	0.00502	CcSEcCtD
Amiloride—SLC9A1—ErbB1 downstream signaling—JUN—sarcoma	0.00155	0.00567	CbGpPWpGaD
Amiloride—Hyperuricaemia—Doxorubicin—sarcoma	0.00155	0.00501	CcSEcCtD
Amiloride—Hyperkalaemia—Epirubicin—sarcoma	0.00152	0.00493	CcSEcCtD
Amiloride—Alopecia—Vincristine—sarcoma	0.00152	0.00491	CcSEcCtD
Amiloride—Jaundice—Etoposide—sarcoma	0.00151	0.00489	CcSEcCtD
Amiloride—PLAU—E2F transcription factor network—MYC—sarcoma	0.0015	0.0055	CbGpPWpGaD
Amiloride—Alopecia—Mitoxantrone—sarcoma	0.00148	0.00478	CcSEcCtD
Amiloride—SLC9A1—G Protein Signaling Pathways—NRAS—sarcoma	0.00147	0.00539	CbGpPWpGaD
Amiloride—SLC9A1—Endothelins—HRAS—sarcoma	0.00147	0.00539	CbGpPWpGaD
Amiloride—Cough—Thiotepa—sarcoma	0.00147	0.00476	CcSEcCtD
Amiloride—Blood uric acid increased—Doxorubicin—sarcoma	0.00146	0.00473	CcSEcCtD
Amiloride—Aplastic anaemia—Epirubicin—sarcoma	0.00146	0.00472	CcSEcCtD
Amiloride—Neck pain—Doxorubicin—sarcoma	0.00145	0.0047	CcSEcCtD
Amiloride—Back pain—Vincristine—sarcoma	0.00144	0.00468	CcSEcCtD
Amiloride—Hepatocellular injury—Doxorubicin—sarcoma	0.00144	0.00465	CcSEcCtD
Amiloride—PLAU—Wnt Signaling Pathway and Pluripotency—CCND1—sarcoma	0.00143	0.00524	CbGpPWpGaD
Amiloride—Arthralgia—Thiotepa—sarcoma	0.00143	0.00464	CcSEcCtD
Amiloride—PLAU—Wnt Signaling Pathway and Pluripotency—JUN—sarcoma	0.00143	0.00523	CbGpPWpGaD
Amiloride—PLAU—Wnt Signaling Pathway and Pluripotency—CTNNB1—sarcoma	0.00142	0.00519	CbGpPWpGaD
Amiloride—Coma—Epirubicin—sarcoma	0.00142	0.00459	CcSEcCtD
Amiloride—Hyperkalaemia—Doxorubicin—sarcoma	0.00141	0.00457	CcSEcCtD
Amiloride—Back pain—Mitoxantrone—sarcoma	0.00141	0.00455	CcSEcCtD
Amiloride—PLAU—Senescence and Autophagy in Cancer—JUN—sarcoma	0.0014	0.00511	CbGpPWpGaD
Amiloride—SLC9A1—ErbB1 downstream signaling—SRC—sarcoma	0.00139	0.00508	CbGpPWpGaD
Amiloride—Confusional state—Thiotepa—sarcoma	0.00139	0.00449	CcSEcCtD
Amiloride—PLAU—Hemostasis—VEGFC—sarcoma	0.00137	0.005	CbGpPWpGaD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—CCND1—sarcoma	0.00136	0.00497	CbGpPWpGaD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—JUN—sarcoma	0.00136	0.00496	CbGpPWpGaD
Amiloride—Aplastic anaemia—Doxorubicin—sarcoma	0.00135	0.00436	CcSEcCtD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—CTNNB1—sarcoma	0.00135	0.00492	CbGpPWpGaD
Amiloride—Vertigo—Vincristine—sarcoma	0.00134	0.00434	CcSEcCtD
Amiloride—SLC9A1—ErbB1 downstream signaling—NRAS—sarcoma	0.00134	0.00489	CbGpPWpGaD
Amiloride—SLC22A4—lymph node—sarcoma	0.00132	0.00317	CbGeAlD
Amiloride—Coma—Doxorubicin—sarcoma	0.00131	0.00425	CcSEcCtD
Amiloride—Anorexia—Thiotepa—sarcoma	0.00131	0.00424	CcSEcCtD
Amiloride—Anorexia—Dactinomycin—sarcoma	0.0013	0.00421	CcSEcCtD
Amiloride—Hepatic function abnormal—Epirubicin—sarcoma	0.00129	0.00417	CcSEcCtD
Amiloride—PLAU—AP-1 transcription factor network—TP53—sarcoma	0.00128	0.00467	CbGpPWpGaD
Amiloride—Cough—Mitoxantrone—sarcoma	0.00127	0.00411	CcSEcCtD
Amiloride—SLC9A1—G Protein Signaling Pathways—KRAS—sarcoma	0.00127	0.00464	CbGpPWpGaD
Amiloride—PLAU—Senescence and Autophagy in Cancer—SRC—sarcoma	0.00125	0.00459	CbGpPWpGaD
Amiloride—Musculoskeletal discomfort—Thiotepa—sarcoma	0.00125	0.00405	CcSEcCtD
Amiloride—Musculoskeletal discomfort—Dactinomycin—sarcoma	0.00124	0.00402	CcSEcCtD
Amiloride—Chest pain—Mitoxantrone—sarcoma	0.00124	0.00401	CcSEcCtD
Amiloride—Arthralgia—Mitoxantrone—sarcoma	0.00124	0.00401	CcSEcCtD
Amiloride—Paraesthesia—Thiotepa—sarcoma	0.00123	0.004	CcSEcCtD
Amiloride—Alopecia—Etoposide—sarcoma	0.00123	0.00398	CcSEcCtD
Amiloride—Somnolence—Thiotepa—sarcoma	0.00122	0.00396	CcSEcCtD
Amiloride—SLC9A1—ErbB1 downstream signaling—EGFR—sarcoma	0.00122	0.00446	CbGpPWpGaD
Amiloride—Dyspepsia—Thiotepa—sarcoma	0.00121	0.00392	CcSEcCtD
Amiloride—Confusional state—Mitoxantrone—sarcoma	0.0012	0.00387	CcSEcCtD
Amiloride—Decreased appetite—Thiotepa—sarcoma	0.00119	0.00387	CcSEcCtD
Amiloride—Hepatic function abnormal—Doxorubicin—sarcoma	0.00119	0.00386	CcSEcCtD
Amiloride—Gastrointestinal disorder—Thiotepa—sarcoma	0.00119	0.00384	CcSEcCtD
Amiloride—Decreased appetite—Dactinomycin—sarcoma	0.00119	0.00384	CcSEcCtD
Amiloride—Fatigue—Thiotepa—sarcoma	0.00118	0.00384	CcSEcCtD
Amiloride—Fatigue—Dactinomycin—sarcoma	0.00118	0.00381	CcSEcCtD
Amiloride—Pain—Thiotepa—sarcoma	0.00118	0.00381	CcSEcCtD
Amiloride—Constipation—Thiotepa—sarcoma	0.00118	0.00381	CcSEcCtD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—NRAS—sarcoma	0.00117	0.00428	CbGpPWpGaD
Amiloride—Back pain—Etoposide—sarcoma	0.00117	0.00379	CcSEcCtD
Amiloride—Shock—Mitoxantrone—sarcoma	0.00117	0.00378	CcSEcCtD
Amiloride—Pain—Dactinomycin—sarcoma	0.00117	0.00378	CcSEcCtD
Amiloride—Muscle spasms—Etoposide—sarcoma	0.00116	0.00377	CcSEcCtD
Amiloride—Anorexia—Vincristine—sarcoma	0.00116	0.00376	CcSEcCtD
Amiloride—SLC9A1—ErbB1 downstream signaling—KRAS—sarcoma	0.00115	0.00421	CbGpPWpGaD
Amiloride—PLAU—Wnt Signaling Pathway and Pluripotency—MYC—sarcoma	0.00115	0.00421	CbGpPWpGaD
Amiloride—Feeling abnormal—Thiotepa—sarcoma	0.00113	0.00367	CcSEcCtD
Amiloride—Anorexia—Mitoxantrone—sarcoma	0.00113	0.00366	CcSEcCtD
Amiloride—Hyponatraemia—Epirubicin—sarcoma	0.00113	0.00366	CcSEcCtD
Amiloride—Pain in extremity—Epirubicin—sarcoma	0.00113	0.00365	CcSEcCtD
Amiloride—Gastrointestinal haemorrhage—Epirubicin—sarcoma	0.00113	0.00365	CcSEcCtD
Amiloride—Feeling abnormal—Dactinomycin—sarcoma	0.00112	0.00364	CcSEcCtD
Amiloride—Gastrointestinal pain—Thiotepa—sarcoma	0.00112	0.00364	CcSEcCtD
Amiloride—Gastrointestinal pain—Dactinomycin—sarcoma	0.00112	0.00361	CcSEcCtD
Amiloride—Musculoskeletal discomfort—Vincristine—sarcoma	0.00111	0.0036	CcSEcCtD
Amiloride—Insomnia—Vincristine—sarcoma	0.0011	0.00357	CcSEcCtD
Amiloride—Paraesthesia—Vincristine—sarcoma	0.00109	0.00354	CcSEcCtD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—MYC—sarcoma	0.00109	0.00399	CbGpPWpGaD
Amiloride—Vertigo—Etoposide—sarcoma	0.00109	0.00352	CcSEcCtD
Amiloride—Abdominal pain—Thiotepa—sarcoma	0.00109	0.00352	CcSEcCtD
Amiloride—Musculoskeletal discomfort—Mitoxantrone—sarcoma	0.00108	0.0035	CcSEcCtD
Amiloride—SLC9A1—G Protein Signaling Pathways—HRAS—sarcoma	0.00108	0.00394	CbGpPWpGaD
Amiloride—Abdominal pain—Dactinomycin—sarcoma	0.00108	0.00349	CcSEcCtD
Amiloride—PLAU—Hemostasis—PLCG1—sarcoma	0.00107	0.00393	CbGpPWpGaD
Amiloride—Paraesthesia—Mitoxantrone—sarcoma	0.00107	0.00345	CcSEcCtD
Amiloride—Decreased appetite—Vincristine—sarcoma	0.00106	0.00343	CcSEcCtD
Amiloride—Dyspnoea—Mitoxantrone—sarcoma	0.00106	0.00343	CcSEcCtD
Amiloride—Cough—Etoposide—sarcoma	0.00106	0.00342	CcSEcCtD
Amiloride—Somnolence—Mitoxantrone—sarcoma	0.00106	0.00342	CcSEcCtD
Amiloride—Gastrointestinal disorder—Vincristine—sarcoma	0.00105	0.00341	CcSEcCtD
Amiloride—Fatigue—Vincristine—sarcoma	0.00105	0.0034	CcSEcCtD
Amiloride—Hyponatraemia—Doxorubicin—sarcoma	0.00105	0.00339	CcSEcCtD
Amiloride—Dyspepsia—Mitoxantrone—sarcoma	0.00104	0.00338	CcSEcCtD
Amiloride—Constipation—Vincristine—sarcoma	0.00104	0.00337	CcSEcCtD
Amiloride—Pain—Vincristine—sarcoma	0.00104	0.00337	CcSEcCtD
Amiloride—Pain in extremity—Doxorubicin—sarcoma	0.00104	0.00337	CcSEcCtD
Amiloride—Gastrointestinal haemorrhage—Doxorubicin—sarcoma	0.00104	0.00337	CcSEcCtD
Amiloride—Decreased appetite—Mitoxantrone—sarcoma	0.00103	0.00334	CcSEcCtD
Amiloride—Chest pain—Etoposide—sarcoma	0.00103	0.00333	CcSEcCtD
Amiloride—Orthostatic hypotension—Epirubicin—sarcoma	0.00103	0.00333	CcSEcCtD
Amiloride—Fatigue—Mitoxantrone—sarcoma	0.00102	0.00331	CcSEcCtD
Amiloride—Pain—Mitoxantrone—sarcoma	0.00101	0.00329	CcSEcCtD
Amiloride—Constipation—Mitoxantrone—sarcoma	0.00101	0.00329	CcSEcCtD
Amiloride—SLC9A1—Regulation of Actin Cytoskeleton—NRAS—sarcoma	0.00101	0.0037	CbGpPWpGaD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—KRAS—sarcoma	0.00101	0.00369	CbGpPWpGaD
Amiloride—Gastrointestinal pain—Vincristine—sarcoma	0.000996	0.00323	CcSEcCtD
Amiloride—Confusional state—Etoposide—sarcoma	0.000995	0.00322	CcSEcCtD
Amiloride—Muscular weakness—Epirubicin—sarcoma	0.000993	0.00322	CcSEcCtD
Amiloride—Asthenia—Thiotepa—sarcoma	0.000986	0.00319	CcSEcCtD
Amiloride—Abdominal distension—Epirubicin—sarcoma	0.00098	0.00317	CcSEcCtD
Amiloride—SLC9A1—ErbB1 downstream signaling—HRAS—sarcoma	0.000979	0.00358	CbGpPWpGaD
Amiloride—Asthenia—Dactinomycin—sarcoma	0.000979	0.00317	CcSEcCtD
Amiloride—Feeling abnormal—Mitoxantrone—sarcoma	0.000978	0.00317	CcSEcCtD
Amiloride—Pruritus—Thiotepa—sarcoma	0.000972	0.00315	CcSEcCtD
Amiloride—Gastrointestinal pain—Mitoxantrone—sarcoma	0.00097	0.00314	CcSEcCtD
Amiloride—Abdominal pain—Vincristine—sarcoma	0.000963	0.00312	CcSEcCtD
Amiloride—Orthostatic hypotension—Doxorubicin—sarcoma	0.000951	0.00308	CcSEcCtD
Amiloride—Angina pectoris—Epirubicin—sarcoma	0.000948	0.00307	CcSEcCtD
Amiloride—PLAU—Wnt Signaling Pathway and Pluripotency—TP53—sarcoma	0.000945	0.00345	CbGpPWpGaD
Amiloride—Anorexia—Etoposide—sarcoma	0.000941	0.00305	CcSEcCtD
Amiloride—Diarrhoea—Thiotepa—sarcoma	0.00094	0.00304	CcSEcCtD
Amiloride—Abdominal pain—Mitoxantrone—sarcoma	0.000938	0.00304	CcSEcCtD
Amiloride—Diarrhoea—Dactinomycin—sarcoma	0.000933	0.00302	CcSEcCtD
Amiloride—PLAU—Senescence and Autophagy in Cancer—TP53—sarcoma	0.000923	0.00338	CbGpPWpGaD
Amiloride—SLC9A1—Regulation of Actin Cytoskeleton—EGFR—sarcoma	0.000921	0.00337	CbGpPWpGaD
Amiloride—Muscular weakness—Doxorubicin—sarcoma	0.000919	0.00298	CcSEcCtD
Amiloride—Neutropenia—Epirubicin—sarcoma	0.00091	0.00295	CcSEcCtD
Amiloride—Dysuria—Epirubicin—sarcoma	0.00091	0.00295	CcSEcCtD
Amiloride—Dizziness—Thiotepa—sarcoma	0.000909	0.00294	CcSEcCtD
Amiloride—Abdominal distension—Doxorubicin—sarcoma	0.000906	0.00294	CcSEcCtD
Amiloride—Pollakiuria—Epirubicin—sarcoma	0.000899	0.00291	CcSEcCtD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—TP53—sarcoma	0.000896	0.00328	CbGpPWpGaD
Amiloride—Paraesthesia—Etoposide—sarcoma	0.000886	0.00287	CcSEcCtD
Amiloride—PLAU—Senescence and Autophagy in Cancer—HRAS—sarcoma	0.000883	0.00323	CbGpPWpGaD
Amiloride—Dyspnoea—Etoposide—sarcoma	0.00088	0.00285	CcSEcCtD
Amiloride—Somnolence—Etoposide—sarcoma	0.000878	0.00284	CcSEcCtD
Amiloride—Angina pectoris—Doxorubicin—sarcoma	0.000877	0.00284	CcSEcCtD
Amiloride—Asthenia—Vincristine—sarcoma	0.000874	0.00283	CcSEcCtD
Amiloride—Vomiting—Thiotepa—sarcoma	0.000874	0.00283	CcSEcCtD
Amiloride—SLC9A1—Regulation of Actin Cytoskeleton—KRAS—sarcoma	0.00087	0.00318	CbGpPWpGaD
Amiloride—SLC9A1—Disease—TLE1—sarcoma	0.000869	0.00318	CbGpPWpGaD
Amiloride—Vomiting—Dactinomycin—sarcoma	0.000867	0.00281	CcSEcCtD
Amiloride—Rash—Thiotepa—sarcoma	0.000866	0.00281	CcSEcCtD
Amiloride—Dermatitis—Thiotepa—sarcoma	0.000866	0.0028	CcSEcCtD
Amiloride—Headache—Thiotepa—sarcoma	0.000861	0.00279	CcSEcCtD
Amiloride—Rash—Dactinomycin—sarcoma	0.00086	0.00278	CcSEcCtD
Amiloride—Decreased appetite—Etoposide—sarcoma	0.000858	0.00278	CcSEcCtD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—HRAS—sarcoma	0.000857	0.00313	CbGpPWpGaD
Amiloride—Gastrointestinal disorder—Etoposide—sarcoma	0.000852	0.00276	CcSEcCtD
Amiloride—Asthenia—Mitoxantrone—sarcoma	0.000851	0.00276	CcSEcCtD
Amiloride—Fatigue—Etoposide—sarcoma	0.000851	0.00276	CcSEcCtD
Amiloride—Jaundice—Epirubicin—sarcoma	0.000846	0.00274	CcSEcCtD
Amiloride—Pain—Etoposide—sarcoma	0.000844	0.00273	CcSEcCtD
Amiloride—Constipation—Etoposide—sarcoma	0.000844	0.00273	CcSEcCtD
Amiloride—Dysuria—Doxorubicin—sarcoma	0.000842	0.00273	CcSEcCtD
Amiloride—Neutropenia—Doxorubicin—sarcoma	0.000842	0.00273	CcSEcCtD
Amiloride—Diarrhoea—Vincristine—sarcoma	0.000834	0.0027	CcSEcCtD
Amiloride—Pollakiuria—Doxorubicin—sarcoma	0.000832	0.00269	CcSEcCtD
Amiloride—Nausea—Thiotepa—sarcoma	0.000816	0.00264	CcSEcCtD
Amiloride—Feeling abnormal—Etoposide—sarcoma	0.000813	0.00263	CcSEcCtD
Amiloride—Diarrhoea—Mitoxantrone—sarcoma	0.000812	0.00263	CcSEcCtD
Amiloride—Nausea—Dactinomycin—sarcoma	0.00081	0.00262	CcSEcCtD
Amiloride—Gastrointestinal pain—Etoposide—sarcoma	0.000807	0.00261	CcSEcCtD
Amiloride—Dizziness—Vincristine—sarcoma	0.000806	0.00261	CcSEcCtD
Amiloride—Bradycardia—Epirubicin—sarcoma	0.000793	0.00257	CcSEcCtD
Amiloride—SLC9A1—Disease—NPM1—sarcoma	0.000784	0.00287	CbGpPWpGaD
Amiloride—Haemoglobin—Epirubicin—sarcoma	0.000783	0.00253	CcSEcCtD
Amiloride—Jaundice—Doxorubicin—sarcoma	0.000782	0.00253	CcSEcCtD
Amiloride—Abdominal pain—Etoposide—sarcoma	0.00078	0.00253	CcSEcCtD
Amiloride—Haemorrhage—Epirubicin—sarcoma	0.000779	0.00252	CcSEcCtD
Amiloride—Vomiting—Vincristine—sarcoma	0.000775	0.00251	CcSEcCtD
Amiloride—Rash—Vincristine—sarcoma	0.000768	0.00249	CcSEcCtD
Amiloride—Dermatitis—Vincristine—sarcoma	0.000768	0.00249	CcSEcCtD
Amiloride—Headache—Vincristine—sarcoma	0.000763	0.00247	CcSEcCtD
Amiloride—Vomiting—Mitoxantrone—sarcoma	0.000755	0.00244	CcSEcCtD
Amiloride—Visual impairment—Epirubicin—sarcoma	0.000751	0.00243	CcSEcCtD
Amiloride—Rash—Mitoxantrone—sarcoma	0.000748	0.00242	CcSEcCtD
Amiloride—Dermatitis—Mitoxantrone—sarcoma	0.000748	0.00242	CcSEcCtD
Amiloride—Headache—Mitoxantrone—sarcoma	0.000743	0.00241	CcSEcCtD
Amiloride—Bradycardia—Doxorubicin—sarcoma	0.000734	0.00238	CcSEcCtD
Amiloride—Tinnitus—Epirubicin—sarcoma	0.000726	0.00235	CcSEcCtD
Amiloride—Haemoglobin—Doxorubicin—sarcoma	0.000724	0.00235	CcSEcCtD
Amiloride—Nausea—Vincristine—sarcoma	0.000724	0.00234	CcSEcCtD
Amiloride—Haemorrhage—Doxorubicin—sarcoma	0.000721	0.00233	CcSEcCtD
Amiloride—Asthenia—Etoposide—sarcoma	0.000708	0.00229	CcSEcCtD
Amiloride—Nausea—Mitoxantrone—sarcoma	0.000705	0.00228	CcSEcCtD
Amiloride—Pruritus—Etoposide—sarcoma	0.000698	0.00226	CcSEcCtD
Amiloride—Visual impairment—Doxorubicin—sarcoma	0.000694	0.00225	CcSEcCtD
Amiloride—Alopecia—Epirubicin—sarcoma	0.000688	0.00223	CcSEcCtD
Amiloride—SLC9A1—Disease—ENO2—sarcoma	0.000679	0.00248	CbGpPWpGaD
Amiloride—Diarrhoea—Etoposide—sarcoma	0.000675	0.00219	CcSEcCtD
Amiloride—Tinnitus—Doxorubicin—sarcoma	0.000672	0.00218	CcSEcCtD
Amiloride—Flatulence—Epirubicin—sarcoma	0.000668	0.00216	CcSEcCtD
Amiloride—Tension—Epirubicin—sarcoma	0.000665	0.00215	CcSEcCtD
Amiloride—Nervousness—Epirubicin—sarcoma	0.000659	0.00213	CcSEcCtD
Amiloride—Back pain—Epirubicin—sarcoma	0.000656	0.00212	CcSEcCtD
Amiloride—Dizziness—Etoposide—sarcoma	0.000653	0.00211	CcSEcCtD
Amiloride—Muscle spasms—Epirubicin—sarcoma	0.000652	0.00211	CcSEcCtD
Amiloride—Alopecia—Doxorubicin—sarcoma	0.000637	0.00206	CcSEcCtD
Amiloride—Vomiting—Etoposide—sarcoma	0.000628	0.00203	CcSEcCtD
Amiloride—Rash—Etoposide—sarcoma	0.000622	0.00202	CcSEcCtD
Amiloride—Dermatitis—Etoposide—sarcoma	0.000622	0.00201	CcSEcCtD
Amiloride—Headache—Etoposide—sarcoma	0.000618	0.002	CcSEcCtD
Amiloride—Flatulence—Doxorubicin—sarcoma	0.000618	0.002	CcSEcCtD
Amiloride—Tension—Doxorubicin—sarcoma	0.000616	0.00199	CcSEcCtD
Amiloride—Nervousness—Doxorubicin—sarcoma	0.000609	0.00197	CcSEcCtD
Amiloride—Vertigo—Epirubicin—sarcoma	0.000609	0.00197	CcSEcCtD
Amiloride—Back pain—Doxorubicin—sarcoma	0.000607	0.00196	CcSEcCtD
Amiloride—Muscle spasms—Doxorubicin—sarcoma	0.000603	0.00195	CcSEcCtD
Amiloride—Palpitations—Epirubicin—sarcoma	0.000599	0.00194	CcSEcCtD
Amiloride—Cough—Epirubicin—sarcoma	0.000592	0.00192	CcSEcCtD
Amiloride—Nausea—Etoposide—sarcoma	0.000586	0.0019	CcSEcCtD
Amiloride—Arthralgia—Epirubicin—sarcoma	0.000577	0.00187	CcSEcCtD
Amiloride—Chest pain—Epirubicin—sarcoma	0.000577	0.00187	CcSEcCtD
Amiloride—SLC9A1—Disease—PLCG1—sarcoma	0.000576	0.00211	CbGpPWpGaD
Amiloride—SLC9A1—Metabolism—ENO2—sarcoma	0.000569	0.00208	CbGpPWpGaD
Amiloride—SLC9A1—Metabolism—HBA1—sarcoma	0.000565	0.00207	CbGpPWpGaD
Amiloride—Vertigo—Doxorubicin—sarcoma	0.000564	0.00183	CcSEcCtD
Amiloride—Confusional state—Epirubicin—sarcoma	0.000558	0.00181	CcSEcCtD
Amiloride—Palpitations—Doxorubicin—sarcoma	0.000554	0.0018	CcSEcCtD
Amiloride—SLC9A1—Disease—CXCR4—sarcoma	0.000554	0.00202	CbGpPWpGaD
Amiloride—Cough—Doxorubicin—sarcoma	0.000547	0.00177	CcSEcCtD
Amiloride—Shock—Epirubicin—sarcoma	0.000544	0.00176	CcSEcCtD
Amiloride—Arthralgia—Doxorubicin—sarcoma	0.000534	0.00173	CcSEcCtD
Amiloride—Chest pain—Doxorubicin—sarcoma	0.000534	0.00173	CcSEcCtD
Amiloride—Anorexia—Epirubicin—sarcoma	0.000527	0.00171	CcSEcCtD
Amiloride—Confusional state—Doxorubicin—sarcoma	0.000516	0.00167	CcSEcCtD
Amiloride—Musculoskeletal discomfort—Epirubicin—sarcoma	0.000504	0.00163	CcSEcCtD
Amiloride—Shock—Doxorubicin—sarcoma	0.000504	0.00163	CcSEcCtD
Amiloride—Insomnia—Epirubicin—sarcoma	0.0005	0.00162	CcSEcCtD
Amiloride—Paraesthesia—Epirubicin—sarcoma	0.000497	0.00161	CcSEcCtD
Amiloride—Dyspnoea—Epirubicin—sarcoma	0.000493	0.0016	CcSEcCtD
Amiloride—Somnolence—Epirubicin—sarcoma	0.000492	0.00159	CcSEcCtD
Amiloride—Anorexia—Doxorubicin—sarcoma	0.000488	0.00158	CcSEcCtD
Amiloride—Dyspepsia—Epirubicin—sarcoma	0.000487	0.00158	CcSEcCtD
Amiloride—SLC9A1—Metabolism—PLCG1—sarcoma	0.000483	0.00176	CbGpPWpGaD
Amiloride—Decreased appetite—Epirubicin—sarcoma	0.000481	0.00156	CcSEcCtD
Amiloride—Gastrointestinal disorder—Epirubicin—sarcoma	0.000478	0.00155	CcSEcCtD
Amiloride—Fatigue—Epirubicin—sarcoma	0.000477	0.00154	CcSEcCtD
Amiloride—Constipation—Epirubicin—sarcoma	0.000473	0.00153	CcSEcCtD
Amiloride—Pain—Epirubicin—sarcoma	0.000473	0.00153	CcSEcCtD
Amiloride—Musculoskeletal discomfort—Doxorubicin—sarcoma	0.000466	0.00151	CcSEcCtD
Amiloride—Insomnia—Doxorubicin—sarcoma	0.000463	0.0015	CcSEcCtD
Amiloride—Paraesthesia—Doxorubicin—sarcoma	0.00046	0.00149	CcSEcCtD
Amiloride—Dyspnoea—Doxorubicin—sarcoma	0.000456	0.00148	CcSEcCtD
Amiloride—Feeling abnormal—Epirubicin—sarcoma	0.000456	0.00148	CcSEcCtD
Amiloride—Somnolence—Doxorubicin—sarcoma	0.000455	0.00147	CcSEcCtD
Amiloride—Gastrointestinal pain—Epirubicin—sarcoma	0.000452	0.00147	CcSEcCtD
Amiloride—Dyspepsia—Doxorubicin—sarcoma	0.000451	0.00146	CcSEcCtD
Amiloride—Decreased appetite—Doxorubicin—sarcoma	0.000445	0.00144	CcSEcCtD
Amiloride—Gastrointestinal disorder—Doxorubicin—sarcoma	0.000442	0.00143	CcSEcCtD
Amiloride—Fatigue—Doxorubicin—sarcoma	0.000441	0.00143	CcSEcCtD
Amiloride—Pain—Doxorubicin—sarcoma	0.000438	0.00142	CcSEcCtD
Amiloride—Constipation—Doxorubicin—sarcoma	0.000438	0.00142	CcSEcCtD
Amiloride—Abdominal pain—Epirubicin—sarcoma	0.000437	0.00142	CcSEcCtD
Amiloride—Feeling abnormal—Doxorubicin—sarcoma	0.000422	0.00137	CcSEcCtD
Amiloride—Gastrointestinal pain—Doxorubicin—sarcoma	0.000419	0.00136	CcSEcCtD
Amiloride—SLC9A1—Disease—FOXO1—sarcoma	0.000409	0.0015	CbGpPWpGaD
Amiloride—PLAU—Hemostasis—IL2—sarcoma	0.000409	0.00149	CbGpPWpGaD
Amiloride—SLC9A1—Disease—PDGFRB—sarcoma	0.000408	0.00149	CbGpPWpGaD
Amiloride—Abdominal pain—Doxorubicin—sarcoma	0.000405	0.00131	CcSEcCtD
Amiloride—SLC9A1—Disease—PDGFRA—sarcoma	0.000402	0.00147	CbGpPWpGaD
Amiloride—Asthenia—Epirubicin—sarcoma	0.000397	0.00129	CcSEcCtD
Amiloride—Pruritus—Epirubicin—sarcoma	0.000391	0.00127	CcSEcCtD
Amiloride—Diarrhoea—Epirubicin—sarcoma	0.000379	0.00123	CcSEcCtD
Amiloride—Asthenia—Doxorubicin—sarcoma	0.000367	0.00119	CcSEcCtD
Amiloride—Dizziness—Epirubicin—sarcoma	0.000366	0.00118	CcSEcCtD
Amiloride—Pruritus—Doxorubicin—sarcoma	0.000362	0.00117	CcSEcCtD
Amiloride—PLAU—Hemostasis—SRC—sarcoma	0.000356	0.0013	CbGpPWpGaD
Amiloride—Vomiting—Epirubicin—sarcoma	0.000352	0.00114	CcSEcCtD
Amiloride—Diarrhoea—Doxorubicin—sarcoma	0.00035	0.00113	CcSEcCtD
Amiloride—Rash—Epirubicin—sarcoma	0.000349	0.00113	CcSEcCtD
Amiloride—Dermatitis—Epirubicin—sarcoma	0.000349	0.00113	CcSEcCtD
Amiloride—PLAU—Hemostasis—VEGFA—sarcoma	0.000347	0.00127	CbGpPWpGaD
Amiloride—Headache—Epirubicin—sarcoma	0.000347	0.00112	CcSEcCtD
Amiloride—PLAU—Hemostasis—NRAS—sarcoma	0.000343	0.00125	CbGpPWpGaD
Amiloride—Dizziness—Doxorubicin—sarcoma	0.000339	0.0011	CcSEcCtD
Amiloride—Nausea—Epirubicin—sarcoma	0.000329	0.00106	CcSEcCtD
Amiloride—Vomiting—Doxorubicin—sarcoma	0.000326	0.00105	CcSEcCtD
Amiloride—Rash—Doxorubicin—sarcoma	0.000323	0.00105	CcSEcCtD
Amiloride—Dermatitis—Doxorubicin—sarcoma	0.000323	0.00104	CcSEcCtD
Amiloride—Headache—Doxorubicin—sarcoma	0.000321	0.00104	CcSEcCtD
Amiloride—SLC9A1—Disease—KIT—sarcoma	0.000312	0.00114	CbGpPWpGaD
Amiloride—Nausea—Doxorubicin—sarcoma	0.000304	0.000985	CcSEcCtD
Amiloride—SLC9A1—Disease—CREB1—sarcoma	0.000297	0.00108	CbGpPWpGaD
Amiloride—PLAU—Hemostasis—KRAS—sarcoma	0.000295	0.00108	CbGpPWpGaD
Amiloride—SLC22A2—Transmission across Chemical Synapses—CREB1—sarcoma	0.000279	0.00102	CbGpPWpGaD
Amiloride—PLAU—Hemostasis—TP53—sarcoma	0.000262	0.000959	CbGpPWpGaD
Amiloride—SLC22A1—Transmission across Chemical Synapses—CREB1—sarcoma	0.00026	0.00095	CbGpPWpGaD
Amiloride—PLAU—Hemostasis—HRAS—sarcoma	0.000251	0.000917	CbGpPWpGaD
Amiloride—SLC9A1—Disease—MDM2—sarcoma	0.000245	0.000897	CbGpPWpGaD
Amiloride—SLC22A2—Transmission across Chemical Synapses—MDM2—sarcoma	0.000231	0.000843	CbGpPWpGaD
Amiloride—SLC22A1—Transmission across Chemical Synapses—MDM2—sarcoma	0.000215	0.000786	CbGpPWpGaD
Amiloride—SLC22A2—Neuronal System—CREB1—sarcoma	0.000213	0.000781	CbGpPWpGaD
Amiloride—SLC9A1—Disease—CTNNB1—sarcoma	0.000212	0.000774	CbGpPWpGaD
Amiloride—SLC22A1—Neuronal System—CREB1—sarcoma	0.000199	0.000728	CbGpPWpGaD
Amiloride—SLC9A1—Disease—SRC—sarcoma	0.000191	0.0007	CbGpPWpGaD
Amiloride—SLC9A1—Disease—NRAS—sarcoma	0.000184	0.000673	CbGpPWpGaD
Amiloride—SLC22A2—Neuronal System—MDM2—sarcoma	0.000177	0.000646	CbGpPWpGaD
Amiloride—SLC9A1—Disease—MYC—sarcoma	0.000171	0.000627	CbGpPWpGaD
Amiloride—SLC9A1—Disease—EGFR—sarcoma	0.000168	0.000613	CbGpPWpGaD
Amiloride—SLC22A1—Neuronal System—MDM2—sarcoma	0.000165	0.000602	CbGpPWpGaD
Amiloride—SLC9A1—Disease—KRAS—sarcoma	0.000158	0.000579	CbGpPWpGaD
Amiloride—SLC9A1—Disease—HRAS—sarcoma	0.000135	0.000492	CbGpPWpGaD
Amiloride—SLC22A2—Transmission across Chemical Synapses—HRAS—sarcoma	0.000126	0.000463	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—ENO2—sarcoma	0.000123	0.00045	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—HBA1—sarcoma	0.000122	0.000447	CbGpPWpGaD
Amiloride—SLC22A1—Transmission across Chemical Synapses—HRAS—sarcoma	0.000118	0.000431	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—ENO2—sarcoma	0.000115	0.00042	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—HBA1—sarcoma	0.000114	0.000417	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—PLCG1—sarcoma	0.000104	0.000382	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—PLCG1—sarcoma	9.74e-05	0.000356	CbGpPWpGaD
Amiloride—SLC22A2—Neuronal System—HRAS—sarcoma	9.69e-05	0.000354	CbGpPWpGaD
Amiloride—SLC22A1—Neuronal System—HRAS—sarcoma	9.03e-05	0.00033	CbGpPWpGaD
